By Ann Mcnary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Funding: No funding was provided for the preparation of this article. Disclosures: Ms. McNary
Innov Clin Neurosci. 2018;15(5–6):11–12 Dr. Bestha is with the Carolinas Healthcare System in Charlotte, North Carolina. Funding/financial disclosures. The author has no conflicts of interest relevant to the content of
by Amanda K. Kitten, PharmD; Sarah A. Hallowell, PharmD; Stephen Saklad, PharmD, BCPP; and Kirk E. Evoy, PharmD, BCACP, BC-ADM, CTTS Drs. Kitten, Hallowell, Saklad, and Evoy are with the
by Sandeep Grover, MD; Aditya Somani, MD; Neeru Sahni, MD; Sahil Mehta, DM; Swati Choudhary, MBBS; Rahul Kumar Chakravarty, MBBS; and Anju Moni Rabha, MBBS Drs. Grover, Somani, Sahni, Mehta,
Dear Editor: In the 10th edition of the International Classification of Diseases (ICD-10) the category “acute and transient psychotic disorder” (ATPD; F23) was introduced, grouping several psychotic conditions that were
Dear Editor: Marijuana is one of the most common illegal drugs consumed in the United States. Its use is growing in popularity, especially among young people, partly because of increasing
Dear Colleagues: Thirty years ago, the Positive and Negative Syndrome Scale (PANSS) was developed and published by Stanley Kay, Abraham Fiszbein, and Lewis Opler to identify the presence and severity
by Nina R. Schooler, PhD Dr. Schooler is Professor of Psychiatry at SUNY Downstate Medical Center in Brooklyn, New York. Funding: No funding was provided for this article. Disclosures: The
by Stacy Liechti, PhD; Gianna Capodilupo, MA; Douglas J. Opler, MD; Mark Opler, PhD, MPH; and Lawrence H. Yang, PhD Dr. Liechti is Lead Research Consultant at the PANSS Institute
by Philip D. Harvey, PhD; Anzalee Khan, PhD; and Richard S. E. Keefe, PhD Dr. Harvey is Professor of Psychiatry and Behavioral Sciences at University of Miami School of Medicine
by Philip D. Harvey, PhD; Cynthia O. Siu, PhD; and Antony D. Loebel, MD Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and
by Anzalee Khan, PhD; Lora Liharska, MS; Philip D. Harvey, PhD; Alexandra Atkins, PhD; Daniel Ulshen, BA; and Richard S.E. Keefe, PhD Dr. Khan is Senior Biostatistician at NeuroCog Trials
by Ariana E. Anderson, PhD; Steven P. Reise, PhD; Stephen R. Marder, MD; Maxwell Mansolf, MS; Carol Han, BS; and Robert M. Bilder, PhD Dr. Anderson is with the Department
by Seth C. Hopkins, PhD; Ajay Ogirala, PhD, Antony Loebel, MD; and Kenneth S. Koblan, PhD Drs. Hopkins, Ogirala, Loebel, and Koblan are with Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts. Funding:
by Farnaz Zamani Esfahlani, MS; Hiroki Sayama, DSc; Katherine Frost Visser, MS; and Gregory P. Strauss, PhD Ms. Zamani Esfahlani is a PhD candidate in the Systems Science program at
by Jean-Pierre Lindenmayer, MD Dr. Lindenmayer is Clinical Professor of the Department of Psychiatry at the NYU School of Medicine in New York, New York. Funding: No funding was provided
by Mark G. A. Opler, PhD, MPH; Christian Yavorsky, PhD; and David G Daniel, MD Dr. Opler is Adjunct Assistant Professor at NYU School of Medicine and Chief Research Officer
by David R. Spiegel, MD, FAPA; Aaron B. Nelson, MD; David C. Lieb, MD, FACE, FACP; Alexander M. Pattison, MD; Justin Smith, DO; Patrice Zigrossi, MD; and Erin Godbout, MD
by Sriram Ramaswamy, MD; David Driscoll, PhD; and Lynette M. Smith, PhD Dr. Ramaswamy is with the Department of Psychiatry, Creighton University School of Medicine, Omaha, Nebraska, and the VA
Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI)
by Søren D. Østergaard, MD, PhD; Mark G. A. Opler, PhD, MPh; and Christoph U. Correll, MD Dr. Østergaard is Associate Professor at Aarhus University in Denmark. Dr. Opler is
Read More